0001209191-24-000071.txt : 20240102
0001209191-24-000071.hdr.sgml : 20240102
20240102160746
ACCESSION NUMBER: 0001209191-24-000071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231229
FILED AS OF DATE: 20240102
DATE AS OF CHANGE: 20240102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KAKKIS EMIL D
CENTRAL INDEX KEY: 0001248093
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36276
FILM NUMBER: 24502433
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc.
CENTRAL INDEX KEY: 0001515673
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 272546083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-483-8800
MAIL ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-29
0
0001515673
Ultragenyx Pharmaceutical Inc.
RARE
0001248093
KAKKIS EMIL D
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO
CA
94949
1
1
0
0
President & CEO
0
Common Stock
2023-12-29
4
S
0
30000
47.87
D
569770
D
Common Stock
2263985
I
By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.54 to $48.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes 27 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
/s/ Karah Parschauer, attorney-in-fact
2024-01-02